News

All Hat, No Cattle: When Urban Hospitals Pretend to be Rural

You’ve probably heard the expression, “all hat, no cattle.” It describes someone who wears trappings of a cowboy but has never stepped foot on a ranch. Well, the phrase also

Bipartisan Senate Group Unveils 340B Drug Discount Bill (1)

A bipartisan group of senators released new 340B drug discount legislation on Wednesday, the result of a years-long congressional effort to overhaul a program that pits drugmakers against hospitals.

Trump administration revises rebate pilot for 340B drug discount program, angering hospitals

HRSA says pilot will improve transparency by providing greater visibility into 340B transactions.

Putting Vulnerable Patients First Means Demanding Section 340B Transparency

When President George H.W. Bush signed a bill into law creating the Section 340B Drug Pricing Program in 1992, it had broad bipartisan support. The goal of the program was

Haitian fraudster’s eye-popping taxpayer-backed drug scam puts Congress on the hunt

Jean Jethro Alexandre bought a $2.5M mansion, Bentley and Mercedes fleet before being ordered to pay $14.3M in restitution.

Nationwide private-equity backed hospital chain announces shift to nonprofit business model

A nationwide health system of 11 hospitals is dropping its for-profit business model and switching to a nonprofit model, citing its desire to deliver “quality care in rural and mid-sized

Federal 340B drug program accused of health care abuse

FOX Business' Gerri Willis reports on health care abuse accusations against the federal 340B drug program and the impact of costs on 'Varney & Co.'

The Great 340B Healthcare Grift

A federal judge shows how this hospital ‘discount’ fleeces drug makers and patients.

How corporate welfare for hospitals is raising health care costs

A drug discount program has fueled consolidation and incentivized prescribing more expensive medications.

How a Company Makes Millions Off a Hospital Program Meant to Help the Poor

A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills.
Scroll to Top